Remove IPO Remove M&A Remove Pharmaceutical
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in. Let’s dig in.

M&A 40
article thumbnail

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022.

M&A 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2020 Life Sciences M&A Year in Review

Cooley M&A

General Trends in Life Sciences M&A. In contrast, aggregate M&A deal value for the life sciences sector was down nearly 50% when compared to 2019, with the first half of 2020 particularly dismal in the wake of market uncertainty caused by the pandemic.

M&A 40
article thumbnail

How Common are Postmerger Divestitures of Acquired Company Units?

M&A Leadership Council

Fundamentals of M&A: An Excerpt from The Art of M&A Book Series. By Alexandra Reed Lajoux, Board of M&A Standards/Founding Principal at CapEx . How Common are Postmerger Divestitures of Acquired Company Units? . It depends on how long a timeline for divestiture you are considering. What is a sell-off? .

article thumbnail

Spot Cyber & IT Challenges Through Improved Due Diligence

M&A Leadership Council

Insights & Advice: An Interview with Two Experts By Mark Herndon, Chairman Emeritus, M&A Leadership Council Cybersecurity and IT due diligence has become one of the most challenging, and also one of the most critical areas of due diligence in any environment. Tell us more about that. What is the business trying to accomplish?

IT 52
article thumbnail

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

General trends in life sciences M&A. While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. driven assets.

M&A 40
article thumbnail

Shareholders vs. Stakeholders - Understanding Corporate Responsibilities

Peak Frameworks

For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. The distinction between them is crucial for understanding a company's obligations, its strategy, and the interplay of interests within its ecosystem. What is a Shareholder?